The current available evidence does not show that GAHT increases oncologic risk for transgender individuals. However, the available evidence is limited and further research into the effects of long-term GAHT is needed. GAHT does not eliminate the potential for malignancy of the patient's natal sex organs and transgender individuals should undergoing cancer screening for all organs present regardless of transition status. Established guidelines for cisgender individuals and can reasonably applied to transgender patients. Comprehensive cancer screening and prevention initiatives centered on relevant anatomy and high-risk behaviors specific for transgender men and women are needed.
The authors have completed the PRISMA-ScR reporting checklist. Available at https://dx.doi.org/10.21037/tau-20-954
Peer Review File
Available at https://dx.doi.org/10.21037/tau-20-954
The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Transl Androl Urol. 2020;9(6):2771-2785. © 2020 AME Publishing Company